Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Insmed (INSM) reported a loss of $1.94 per share in second-quarter 2024, wider than the Zacks Consensus Estimate of a loss of$1.22. In the year-ago quarter, the company posted a loss of $1.78. Insmed generated total revenues of$90.3 million during the quarter, up 17% year over year. Quarterly sales beat the Zacks Consensus Estimate of $88.0 million. Quarter in Detail In the reported quarter, total revenues were generated entirely from product revenues of its only-marketed drug, Arikayce, which is approved ...